Advanced Enzyme Technologies Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.
Published 26 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹3.7K Cr
The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results. The company expects to achieve double-digit revenue growth for the full year, aiming for around 12%+ growth in the remaining quarters. - Growth trajectory is expected to improve in upcoming quarters after a relatively slower Q1. - EBITDA margins are anticipated to normalize to around 30-32% as operational efficiencies improve and energy costs stabilize. - R&D investment will increase to support sustained growth and margin improvement, though immediate margin expansion is not expected. - The U.S.
From Advanced Enzyme Technologies Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Price
₹297
Market Cap
₹3.7K Cr
P/E Ratio
24.0
How does Advanced Enzyme Technologies Ltd rank in Pharmaceuticals & Biotechnology?
Compare Advanced Enzyme Technologies Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹203 Cr, net profit ₹45 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results.
- →Growth in the U.S. market is projected at around 8-10%, driven by branding efforts and gradual strategic changes rather than immediate product launches.
- →The business model focuses on sustained growth with a steady customer base, with 70-80% customers being consistent and 20-30% changing.
- →Growth is expected to come from a combination of new and existing products across various segments.
- →Biocatalysis is considered a high-growth segment, with good growth anticipated particularly in the second half of the year.
- →The company is investing in R&D to foster new product development and enhance productivity, supporting future growth.
- →Incremental sales reversals (around INR 10 crore) from a recent quarter are expected to be realized in subsequent quarters, supporting overall growth.
See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.
🏗️ Capital Expenditure Plans
Yes- →The company plans a total CapEx of INR 123 crore as discussed in the AGM.
- →Approximately INR 20 crore is for normal capital expenditure, INR 50 crore will be for R&D (work in progress), and the remaining is for growth.
- →The CapEx is expected to span FY27, with about INR 20 crore possibly extending into Q2 FY27.
- →The growth CapEx is not allocated to any specific segment but supports manufacturing enzymes for various industries.
- →Current fermentation capacity utilization is around 70-75%, prompting potential capacity expansion.
- →Plans to increase capacity will be taken up in the next quarter.
- →R&D expenditure is targeted to increase productivity and sustain growth but is not expected to immediately boost growth.
- →Overall, the CapEx represents a step-up compared to previous years to support sustained business growth.
See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
📋 Order Book & Pipeline
Yes- →The transcript does not provide explicit details on the current or expected order book or pending orders in precise numbers.
- →Mukund Kabra mentions variability of 20-30% in customers quarter-on-quarter, indicating some order fluctuation.
- →There’s mention of some inventory and order-related delays or complexities at the customer level.
- →Mukund Kabra signals optimism about a "robust pipeline of sales orders" going forward.
- →He advises not to focus heavily on quarter-on-quarter fluctuations as order sizes may vary, with some quarters seeing quick sales and others less.
- →Overall, the management expects a strong momentum from the next quarter.
- →No exact quantitative data on order book or pending orders is provided on page 20 or surrounding context.
Key Metrics
2 of 5 growth signals positive in the Q1 FY27 call.
Revenue
Margin
Capex
Fundraise
Order Book
How does Advanced Enzyme Technologies Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureSee full Pharmaceuticals & Biotechnology sector rankings
Continue your research
What Advanced Enzyme Technologies Ltd's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Ind-Swift Laboratories Ltd (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…
- HIKAL (Q1 FY27)
400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion. Key concall takeaways from Hikal Ltd's Q1 FY27 earnings call — and…
Frequently Asked Questions
What were Advanced Enzyme Technologies Ltd Q1 FY27 results?
The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results. The company expects to achieve double-digit revenue growth for the full year, aiming for around 12%+ growth in the remaining quarters. - Growth trajectory is expected to improve in upcoming quarters after a relatively slower Q1. - EBITDA margins are anticipated to normalize to around 30-32% as operational efficiencies improve and energy costs stabilize. - R&D investment will increase to support sustained growth and margin improvement, though immediate margin expansion is not expected. - The U.S.
What is Advanced Enzyme Technologies Ltd share price analysis?
Advanced Enzyme Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.
Is Advanced Enzyme Technologies Ltd planning capital expenditure?
The company plans a total CapEx of INR 123 crore as discussed in the AGM.
Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.